TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10857839

Group type: EXPERIMENTAL
Intervention: Timolol with systemic beta-blockers
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Brimonidine with systemic beta-blockers
Number of subjects: 926

Group type: COMPARATOR
Intervention: Timolol without systemic beta-blockers
Number of subjects: 926

Group type: COMPARATOR
Intervention: Brimonidine without systemic beta-blockers
Number of subjects: 926
Study: 8775104

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoflurane and Sevoflurane (up to 1.0 MAC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isoflurane vs Sevoflurane
Number of subjects: 0
Study: 1615175

Group type: EXPERIMENTAL
Intervention: Humidification (30 min) followed by postural drainage (20 min) with forced expiration technique
Number of subjects: 7

Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 7
Study: 3091468

Group type: EXPERIMENTAL
Intervention: Rioprostil
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous ranitidine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30517283

Group type: EXPERIMENTAL
Intervention: Occlusal silicone splint (intervention)
Number of subjects: 7
Study: 27087019

Group type: EXPERIMENTAL
Intervention: Imaging-guided LV lead placement using cardiac CT venography, 99m Technetium myocardial perfusion imaging, and speckle-tracking echocardiography
Number of subjects: 182

Group type: COMPARATOR
Intervention: Routine LV lead implantation in a posterolateral region with late electrical activation
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Imaging-guided LV lead placement
Number of subjects: 182

Group type: COMPARATOR
Intervention: Routine LV lead implantation
Number of subjects: 182
Study: 24854306

Group type: EXPERIMENTAL
Intervention: ACTH stimulation test with 250 μg of synthetic ACTH administered intravenously on Days 1, 2, 3, 5, and 7 after traumatic injury
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: CIRCI patients with Δcortisol < 9 μg/dL
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: CIRCI patients
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: CIRCI diagnosis
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Δcortisol < 9 μg/dL
Number of subjects: 70
Study: 23687218

Group type: EXPERIMENTAL
Intervention: Viofor JPS Classic device (pulsed electromagnetic field with low induction of ELF range)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 84
Study: 20096981

Group type: EXPERIMENTAL
Intervention: BioSorb FX biodegradable plates and screws
Number of subjects: 91

Group type: COMPARATOR
Intervention: Titanium miniplates
Number of subjects: 91
Study: 18378836

Group type: EXPERIMENTAL
Intervention: Copay policy (10-25 dollars copayment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Income-based deductible policy (25% coinsurance)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no cost-sharing policy)
Number of subjects: 0
Study: 16020489

Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg twice daily
Number of subjects: 2660

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2660
Study: 12970006

Group type: EXPERIMENTAL
Intervention: FSC (Fluticasone Propionate 250 microg + Salmeterol 50 microg)
Number of subjects: 723
Study: 10434809

Group type: EXPERIMENTAL
Intervention: 20% nitrous oxide in oxygen
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 40% nitrous oxide in oxygen
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 60% nitrous oxide in oxygen
Number of subjects: 10
Study: 7833752

Group type: EXPERIMENTAL
Intervention: Fitness programme (8 exercise classes over 4 weeks)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (specific exercises and back-school education)
Number of subjects: 81
Study: 2163701

Group type: EXPERIMENTAL
Intervention: Freeze-dried amniotic membrane applied at the upper half of the wound (36 patients)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Freeze-dried amniotic membrane applied at the lower half of the wound (29 patients)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Antibiotic-impregnated fine-mesh greased gauze covering remaining areas of the wounds
Number of subjects: 65
Study: 326347

Group type: EXPERIMENTAL
Intervention: BCG vaccine
Number of subjects: 54239

Group type: EXPERIMENTAL
Intervention: Vole bacillus vaccine
Number of subjects: 54239

Group type: COMPARATOR
Intervention: Unvaccinated group
Number of subjects: 54239
Study: 31124918

Group type: EXPERIMENTAL
Intervention: LI‐GCA patients
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 27
Study: 31277561

Group type: EXPERIMENTAL
Intervention: Canakinumab (150 mg subcutaneously)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 27890164

Group type: EXPERIMENTAL
Intervention: Similar task interruption
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Complex task interruption
Number of subjects: 18

Group type: COMPARATOR
Intervention: No interruption
Number of subjects: 18
Study: 25395036

Group type: EXPERIMENTAL
Intervention: Riociguat, individually adjusted up to a maximum dose of 2.5 mg three times daily
Number of subjects: 237
Study: 23519546

Group type: EXPERIMENTAL
Intervention: nebivolol 5-40 mg/day
Number of subjects: 491

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: nebivolol (subgroup analysis for losartan background)
Number of subjects: 491

Group type: COMPARATOR
Intervention: placebo (subgroup analysis for losartan background)
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: nebivolol (subgroup analysis for lisinopril background)
Number of subjects: 491

Group type: COMPARATOR
Intervention: placebo (subgroup analysis for lisinopril background)
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: nebivolol
Number of subjects: 491
Study: 21660636

Group type: EXPERIMENTAL
Intervention: Physiological replacement doses of metreleptin (0.04-0.12 mg/kg q.d.)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Pharmacological doses of metreleptin (0.3 mg/kg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Physiological doses of metreleptin (0.1 mg/kg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 19172849

Group type: EXPERIMENTAL
Intervention: Statin or immunosuppressive therapy
Number of subjects: 63
Study: 16878035

Group type: EXPERIMENTAL
Intervention: rHuEPO 40,000 units administered weekly for up to 12 doses
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: rHuEPO
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 12634643

Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 93

Group type: COMPARATOR
Intervention: Electroablation
Number of subjects: 93
Study: 10969657

Group type: EXPERIMENTAL
Intervention: Category 1 evidence (from randomized controlled trials)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Category 2 evidence (convincing non-experimental evidence)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Interventions without substantial evidence
Number of subjects: 50
Study: 9352691

Group type: EXPERIMENTAL
Intervention: Indwelling Foley catheter
Number of subjects: 100

Group type: COMPARATOR
Intervention: In-out catheterization
Number of subjects: 100

Group type: COMPARATOR
Intervention: Catheterized group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Uncatheterized group
Number of subjects: 100
Study: 8222486

Group type: EXPERIMENTAL
Intervention: ICI 204,219 10 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ICI 204,219 40 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ICI 204,219 100 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ICI 204,219 (all doses)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ICI 204,219
Number of subjects: 30
Study: 3096431

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg four times a day
Number of subjects: 4491

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4491
Study: 29764392

Group type: EXPERIMENTAL
Intervention: 3 of your 5-a-day smoothie label
Number of subjects: 194

Group type: COMPARATOR
Intervention: 1 of your 5-a-day smoothie label
Number of subjects: 194
Study: 27122080

Group type: EXPERIMENTAL
Intervention: Acute aerobic exercise (30 minutes of moderate-intensity) in higher cardiorespiratory fitness group (EIH)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acute aerobic exercise (30 minutes of moderate-intensity) in lower cardiorespiratory fitness group (EIL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (non-exercise intervention)
Number of subjects: 60
Study: 24269603

Group type: EXPERIMENTAL
Intervention: All-inside technique
Number of subjects: 46

Group type: COMPARATOR
Intervention: Classical technique
Number of subjects: 46
Study: 21787454

Group type: COMPARATOR
Intervention: Fibre supplement (FIB)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Healthy eating group with placebo (HLT)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Control (with placebo)
Number of subjects: 3
Study: 20624484

Group type: EXPERIMENTAL
Intervention: Adjusted NNTs using the ARD approach in RCTs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Logistic regression with balanced covariates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulation study
Number of subjects: 0
Study: 19031218

Group type: EXPERIMENTAL
Intervention: Trifolium pratense-derived isoflavones (80 mg red clover isoflavones) daily for 90 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo of equal design
Number of subjects: 60
Study: 15538592

Group type: EXPERIMENTAL
Intervention: 900 mg Hypericum LI 160
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: 20 mg fluoxetine
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 12647424

Group type: EXPERIMENTAL
Intervention: Clomipramine 75‐175 mg daily
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Imipramine 75‐150 mg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Amitriptyline 150 mg
Number of subjects: 34
Study: 10027319

Group type: EXPERIMENTAL
Intervention: Megestrol acetate/ibuprofen
Number of subjects: 73

Group type: COMPARATOR
Intervention: Megestrol acetate/placebo
Number of subjects: 73
Study: 8749597

Group type: EXPERIMENTAL
Intervention: Diane-35
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Microgynon
Number of subjects: 91
Study: 2109678

Group type: EXPERIMENTAL
Intervention: Aldose reductase inhibitors
Number of subjects: 0
Study: 7016450

Group type: EXPERIMENTAL
Intervention: Sodium meclofenamate (200 to 400 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (2.4 to 4.8 g daily)
Number of subjects: 0
Study: 30665602

Group type: EXPERIMENTAL
Intervention: Simultaneous tobacco intervention (TI) combining web-based counseling with nicotine replacement therapy (NRT) during weeks 1-12.
Number of subjects: 67

Group type: COMPARATOR
Intervention: Sequential tobacco intervention (TI) delayed until weeks 13-24.
Number of subjects: 67
Study: 30131639

Group type: EXPERIMENTAL
Intervention: Partial removal of caries (Group I)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Total removal of caries (Group II)
Number of subjects: 49
Study: 27108936

Group type: EXPERIMENTAL
Intervention: Vanoxerine 400 mg
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 24937907

Group type: EXPERIMENTAL
Intervention: Group 1: heavy metal music (13 participants)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Group 2: classical music (13 participants)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Group 3: no music (13 participants)
Number of subjects: 39
Study: 22160549

Group type: EXPERIMENTAL
Intervention: Lidocaine pretreatment (1% lidocaine 2 ml)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo pretreatment (normal saline 2 ml)
Number of subjects: 121
Study: 20962315

Group type: EXPERIMENTAL
Intervention: Carbohydrate-controlled diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fat-controlled diet
Number of subjects: 20
Study: 16884794

Group type: EXPERIMENTAL
Intervention: Blood reduced glutathione (GSH)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Malondialdehyde (MDA)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Increased blood GSH concentrations
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Ischemic CHF etiology
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Non-ischemic CHF etiology
Number of subjects: 52
Study: 16258083

Group type: EXPERIMENTAL
Intervention: Trastuzumab with paclitaxel after doxorubicin and cyclophosphamide (AC)
Number of subjects: 1664

Group type: COMPARATOR
Intervention: Control group (AC followed by paclitaxel without trastuzumab)
Number of subjects: 1664
Study: 11853711

Group type: EXPERIMENTAL
Intervention: 0.12% isopropyl unoprostone (Rescula) applied twice a day for 21 days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo applied twice a day for 21 days
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 0.12% isopropyl unoprostone (Rescula)
Number of subjects: 11
Study: 9798136

Group type: EXPERIMENTAL
Intervention: 0.625‐mg conjugated equine estrogen plus 5‐mg medroxyprogesterone acetate (MPA)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 0.625‐mg conjugated equine estrogen plus 2.5‐mg MPA
Number of subjects: 37
Study: 7825160

Group type: EXPERIMENTAL
Intervention: 6 mg of warfarin per day for 3 days (Group I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 8 mg of warfarin twice a day for 2 or 3 days (Group II)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups (Group I and Group II)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Factor X levels in both groups (Group I and Group II)
Number of subjects: 0
Study: 3364147

Group type: EXPERIMENTAL
Intervention: 10 mg.kg‐1 of 1.5% lidocaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3.3 mg.kg‐1 of 0.5% bupivacaine
Number of subjects: 0
Study: 30305343

Group type: EXPERIMENTAL
Intervention: INPUT program
Number of subjects: 268

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 268
Study: 28033291

Group type: EXPERIMENTAL
Intervention: Adductor canal block (ACB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Femoral nerve block (FNB)
Number of subjects: 60
Study: 24302687

Group type: EXPERIMENTAL
Intervention: Early iron (EI) supplementation (2 mg/kg/day elemental iron)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Late iron (LI) supplementation
Number of subjects: 104
Study: 22273632

Group type: EXPERIMENTAL
Intervention: IL‐1 receptor antagonist (IL‐1Ra) 150 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline placebo 1 ml
Number of subjects: 11
Study: 20381662

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 20
Study: 18308154

Group type: EXPERIMENTAL
Intervention: Circuit-resistance exercise at 40% of 1RM
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Circuit-resistance exercise at 60% of 1RM
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Circuit-resistance exercise at 80% of 1RM
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined loads (40+80+80%)
Number of subjects: 20
Study: 16132790

Group type: EXPERIMENTAL
Intervention: Telephone counseling intervention
Number of subjects: 258

Group type: COMPARATOR
Intervention: Mail intervention
Number of subjects: 258
Study: 14739212

Group type: COMPARATOR
Intervention: Low-dose aspirin 100 mg daily
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin enoxaparin 40 mg
Number of subjects: 160
Study: 10690604

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal sclerotherapy (1% polidocanol)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Octreotide infusion (50 micrograms/h for 12 hours following initial 50 micrograms i.v. bolus)
Number of subjects: 52
Study: 9369912

Group type: EXPERIMENTAL
Intervention: Combined modality treatment of cisplatin‐based chemotherapy and radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy and radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisplatin‐based chemotherapy regimen
Number of subjects: 0
Study: 8335204

Group type: EXPERIMENTAL
Intervention: Heme arginate (3 mg/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of heme arginate (3 mg/kg) and tin protoporphyrin (1 mumol/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Tin protoporphyrin (1 mumol/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination therapy (Heme arginate + Tin protoporphyrin)
Number of subjects: 8
Study: 3090961

Group type: EXPERIMENTAL
Intervention: Urokinase-heparin (Group I)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Lysyl-plasminogen-urokinase-heparin (Group II)
Number of subjects: 67
Study: 2544688

Group type: EXPERIMENTAL
Intervention: Intermittent metoclopramide (regimen A): lorazepam 1 mg orally, dexamethasone 10 mg IV every four hours for three doses, diphenhydramine 0.5 mg/kg IV every four hours for three doses, metoclopramide 1 mg/kg IV bolus every two hours for six doses
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Continuous infusion metoclopramide (regimen B): identical to regimen A except metoclopramide was administered as 1 mg/kg IV bolus followed by 0.5 mg/kg/h for ten hours
Number of subjects: 60
Study: 31147675

Group type: EXPERIMENTAL
Intervention: ipatasertib plus paclitaxel
Number of subjects: 151

Group type: COMPARATOR
Intervention: placebo plus paclitaxel
Number of subjects: 151
Study: 28651898

Group type: EXPERIMENTAL
Intervention: Remote Ischaemic Preconditioning (RIPC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 40
Study: 23849614

Group type: EXPERIMENTAL
Intervention: Breeze cement (Sub-group A, L, C)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Biscem cement (Sub-group A, L, C)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Maxcem Elite (Sub-group A, L, C)
Number of subjects: 45
Study: 21493910

Group type: EXPERIMENTAL
Intervention: SSMP (Stroke Self-Management Program, 8 weeks)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Generic self-management program (6 weeks)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Generic self-management program
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: SSMP
Number of subjects: 143
Study: 19833860

Group type: EXPERIMENTAL
Intervention: Telbivudine 600 mg/d for 7 days
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Telbivudine 1800 mg/d for 7 days
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg (positive calibrator)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 16721396

Group type: EXPERIMENTAL
Intervention: Natural mixed carotenoids supplementation (120,000 IU of beta-carotene daily)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Conventional management with multivitamins (including vitamin A and trace elements)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Natural mixed carotenoids supplementation
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Higher baseline serum carotene concentrations
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Higher baseline CD4 T‐lymphocyte counts
Number of subjects: 331
Study: 15121646

Group type: EXPERIMENTAL
Intervention: Ziprasidone 40 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ziprasidone 80 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ziprasidone 120 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ziprasidone 160 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ziprasidone (all doses)
Number of subjects: 16
Study: 11719126

Group type: EXPERIMENTAL
Intervention: Staged instruction (bronze stage: 50 compressions with pauses, silver stage: 50 compressions to 5 breaths, gold stage: conventional CPR)
Number of subjects: 495

Group type: COMPARATOR
Intervention: Conventional CPR training
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Staged instruction (gold stage)
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Staged instruction (bronze stage)
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Staged instruction (silver stage: 50 compressions to 5 breaths)
Number of subjects: 495
Study: 9223199

Group type: EXPERIMENTAL
Intervention: Subarachnoid neostigmine 100 micrograms
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline (S group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Neostigmine (N group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Propofol (P group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Metoclopramide (M group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Droperidol (D group)
Number of subjects: 100
Study: 8355037

Group type: COMPARATOR
Intervention: 1 year of adjuvant CMFVP chemotherapy
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: 2 years of adjuvant CMFVP chemotherapy
Number of subjects: 445
Study: 3302806

Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 60
Study: 30479561

Group type: EXPERIMENTAL
Intervention: Educational intervention based on Watson's Theory of Human Caring
Number of subjects: 135

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 135
Study: 26701364

Group type: EXPERIMENTAL
Intervention: 1 mg sublingual nitroglycerin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 25711955

Group type: EXPERIMENTAL
Intervention: Higher-protein (HP) breakfast (32 g protein)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Normal-protein (NP) breakfast (12 g protein)
Number of subjects: 35
Study: 23107605

Group type: EXPERIMENTAL
Intervention: EPO
Number of subjects: 53

Group type: COMPARATOR
Intervention: No EPO
Number of subjects: 53

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 53
Study: 21181687

Group type: EXPERIMENTAL
Intervention: Three-hour presentation on the evaluation of ECGs for STEMI (Group 2)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Handout describing the evaluation of ECGs for STEMI (Group 1)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: All students (initial pre-test vs five-month retest)
Number of subjects: 33